This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Keefe, Bruyette & Woods analyst Damon Delmonte initiated coverage on Northpointe Bancshares, Inc. NPB with an Outperform rating and announced a price target of $18. Northpointe Bancshares shares closed at $13.63 on Monday. See how other analysts view this stock.
  • HC Wainwright & Co. analyst Scott Buck initiated coverage on Inuvo, Inc. INUV with a Buy rating and announced a price target of $2. Inuvo shares closed at $0.3538 on Monday. See how other analysts view this stock.
  • Needham analyst Serge Belanger initiated coverage on Ocular Therapeutix, Inc. OCUL with a Buy rating and announced a price target of $15. Ocular Therapeutix shares closed at $7.65 on Monday. See how other analysts view this stock.
  • Jefferies analyst Julien Dumoulin-Smith initiated coverage on Primoris Services Corporation PRIM with a Buy rating and announced a price target of $73. Primoris Services shares closed at $60.51 on Monday. See how other analysts view this stock.
  • Jones Trading analyst Justin Walsh initiated coverage on Serina Therapeutics, Inc. SER with a Buy rating and announced a price target of $11. Serina Therapeutics shares closed at $4.78 on Monday. See how other analysts view this stock.

Considering buying PRIM stock? Here’s what analysts think:

Read This Next:

INUV Logo
INUVInuvo Inc
$0.3670-2.13%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
93.31
Growth
64.62
Quality
-
Value
29.81
Price Trend
Short
Medium
Long
Got Questions? Ask
Which banking stocks will benefit from NPB's rating?
How might Inuvo, Inc. outperform in digital advertising?
What factors could drive Ocular Therapeutix towards $15?
Is there potential for Primoris Services to reach $73?
Which therapeutics companies could follow Serina's lead?
How could analyst upgrades impact small-cap stocks?
What trends are influencing financial analysts' ratings currently?
Could biotech firms see a surge from positive ratings?
Which stocks are analysts bullish on this week?
How will market sentiment shift with these initiations?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: